Arch Therapeutics (ARTH)
(Delayed Data from OTC)
$0.52 USD
0.00 (0.00%)
Updated Aug 28, 2024 02:42 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Arch Therapeutics, Inc. [ARTH]
Reports for Purchase
Showing records 1 - 20 ( 115 total )
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Good Showing at SWAC: Symposium on Advanced Wound Care
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
A Bridge to an Uplist, Commercialization Building
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Getting Closer to Reimbursement - CMS Codes
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
BUY: Cash Constraints Holding Back Commercialization
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
BUY: What?s Next? Capital to Commercialize Could Spark a Higher Valuation
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
BUY: Arch Therapeutics Partners with Centurion Therapeutics
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
BUY: AC5 Topical (clear) Hemostat- Approved, Launch Begins
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Still Awaiting Launch Strategy; F3Q20 Financials; Reducing PT to $1.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Still Waiting on Commercialization; CE Mark Received; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Additional Supplier and Manufacturing Processes Cleared; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
We are dropping coverage due to the reallocation of research resources
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
F2019 Financials Reported; Final Regulatory Hurdles in Sight; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
The company is dropping coverage of the following stocks
Provider: IFS Securities, Inc.
Analyst: Research Department
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Awaiting Launch Strategy Clarity; CE Mark Timeline; AC5 Anti-Microbial Potential; Modulating Price Target to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R